SELECT PUBLICATIONS
Cassidy J et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Proc ASCO GI Cancers Symposium 2007;Abstract 270.
D’Angelica M et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007;14(2):759-65. Abstract
Giantonio BJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2005;Abstract 2.
Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10(Suppl 3):40-8. Abstract
Gotlib V et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006;17(10):1227-9. Abstract
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Kuo T, Fisher GA. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clin Colorectal Cancer 2005;5(Suppl 2):62-70. Abstract
Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: Pathology and management. Oncology (Williston Park) 2006;20(11):1373-82. Abstract
Reidy DL et al. Bevacizumab 5 mg/kg can be safely infused over ten minutes. Proc ASCO GI Cancers Symposium 2007;Abstract 355.
Saltz LB et al. Bevacizumab in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Proc ASCO GI Cancers Symposium 2007;Abstract 238.
Saltz LB. Metastatic colorectal cancer: Is there one standard approach? Oncology (Williston Park) 2005;19(9):1147-54. Abstract
Saltz LB et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905-14. Abstract
Scappaticci FA et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80. Abstract
Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial. Clin Colorectal Cancer 2006;6(4):261-4. Abstract
Vallbohmer D et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005;23(15):3536-44. Abstract
Van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract
